ARS concluded a number of contracts with the leading generic pharmaceutical company in Russia. ARS CRO will provide full support in conducting local bioequivalence clinical trials for Sovosbuvir, Lapatinib, Inburtinib, Fingolimod, Gefitinib, Sorafenib, and others. The study for Lapatinib will be in patients. ARS clinical experts have solid experience in BE/PK clinical research. They will manage these projects from the very studies design through the clinical studies reports. The trials will be performed in accordance with the Russian drug registration requirements.